# Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

> **NCT00528073** · PHASE2 · COMPLETED · sponsor: **Alfasigma S.p.A.** · enrollment: 410 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Rifaximin-EIR

## Key facts

- **NCT ID:** NCT00528073
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-03
- **Final completion:** 2009-10
- **Target enrollment:** 410 (ACTUAL)
- **Last updated:** 2010-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528073, "Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT00528073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*